# Factor IX as Adjunctive Therapy to Emicizumab (EMIX)

> **NCT05281718** · EARLY_PHASE1 · COMPLETED · sponsor: **Tulane University** · enrollment: 12 (actual)

## Conditions studied

- Hemophilia A

## Interventions

- **DRUG:** Factor IX

## Key facts

- **NCT ID:** NCT05281718
- **Lead sponsor:** Tulane University
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-08-01
- **Primary completion:** 2024-03-07
- **Final completion:** 2024-07-14
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2025-01-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05281718

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05281718, "Factor IX as Adjunctive Therapy to Emicizumab (EMIX)". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT05281718. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*